Company Encyclopedia
View More
name
JACOBSON PHARMA
02633.HK
Jacobson Pharma Corporation Limited, through its subsidiaries, engages in the research, development, production, sale, and distribution of medicine and drugs in Hong Kong, Mainland China, Macau, Singapore, and internationally. It operates in two segments, Generic Drugs and Branded Healthcare. The company offers generic drugs for various therapeutic categories, including cardiovascular, central nervous, gastrointestinal, respiratory, musculo-skeletal, genito-urinary, anti-infectives, endocrine and metabolic, dermatological, and anti-allergic. It also provides branded medicines; health and wellness products; proprietary Chinese medicines; treasury services; and management services.
1.450 T
02633.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking30/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.97%B
    • Profit Margin19.73%A
    • Gross Margin44.07%B
  • Growth ScoreD
    • Revenue YoY-1.88%D
    • Net Profit YoY19.49%B
    • Total Assets YoY-2.19%D
    • Net Assets YoY-8.03%D
  • Cash ScoreC
    • Cash Flow Margin506.79%C
    • OCF YoY-1.88%D
  • Operating ScoreC
    • Turnover0.43C
  • Debt ScoreB
    • Gearing Ratio35.97%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jacobson Pharma Posts Slight Rise in Fiscal H1 Profit; Shares Fall 7%

    Jacobson Pharma Posts Slight Rise in Fiscal H1 Profit; Shares Fall 7%

    marketscreener·
    HK
    02633
    +1.61%
    marketscreener·
    HK
    02633
    +1.61%

    "Performance" Jacobson Pharma's interim net profit is HKD 142 million, an increase of 1.2%, with a dividend of 4.25 cents

    JACOBSON PHARMA announced its interim results for the six months ended September, with revenue of HKD 767 million, a year-on-year decrease of 5.4%. It recorded a net profit of HKD 142 million, an increase of 1.2%, with earnings per share of HKD 0.0712. The interim dividend is HKD 0.0425, compared to HKD 0.035 in the same period last year

    AASTOCKS·
    HK
    02633
    +1.61%
    AASTOCKS·
    HK
    02633
    +1.61%

    Jacobson Pharma Reports Interim Results with Increased Shareholder Dividends

    Jacobson Pharma Corporation Limited reported a 5.4% revenue decrease to HK$766.6 million for the six months ending 30 September 2025. Despite this, profit attributable to shareholders rose by 1.2% to HK$142.0 million. The Board declared an interim dividend of HK4.25 cents per share, a 21.4% increase from the previous year. The stock is rated Hold with a HK$1.50 price target. Jacobson Pharma focuses on generic drugs and proprietary medicines, listed on the Hong Kong Stock Exchange under code 2633.

    Tip Ranks·
    HK
    02633
    +1.61%
    Tip Ranks·
    HK
    02633
    +1.61%

    Jacobson Pharma Corporation Ltd. announces interim dividend of HKD 0.0425 per share

    Jacobson Pharma Corporation Ltd. has declared an interim dividend of HKD 0.0425 per share for the six months ending 30 September 2025. The record date is 4 December 2025, with payment on 18 December 2025. This announcement was made on November 18, 2025.

    Reuters·
    HK
    02633
    +1.61%
    Reuters·
    HK
    02633
    +1.61%

    Jacobson Pharma Board to Review Interim Results and Dividend

    Jacobson Pharma Corporation Ltd. will hold a board meeting on November 18, 2025, to review interim results for the six months ending September 30, 2025, and to consider an interim dividend payment along with other business matters.

    Reuters·
    HK
    02633
    +1.61%
    Reuters·
    HK
    02633
    +1.61%
    © 2025 Longbridge｜Disclaimer